4.6 Article

Genome-wide association study identifies CD1A associated with rate of increase in plasma neurofilament light in non-demented elders

Journal

AGING-US
Volume 11, Issue 13, Pages 4521-4535

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/aging.102066

Keywords

genome-wide association study; plasma NFL; non-demented elders; CD1A; genetic factors

Funding

  1. National Natural Science Foundation of China [91849126]
  2. National Key R&D Program of China [2018YFC1314700]
  3. Shanghai Municipal Science and Technology Major Project [2018SHZDZX01]
  4. ZHANGJIANG LAB
  5. Tianqiao and Chrissy Chen Institute
  6. Frontiers Center for Brain Science of Ministry of Education, Fudan University
  7. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  8. DOD ADNI (Department of Defense award) [W81XWH-12-2-0012]
  9. National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
  10. AbbVie
  11. Alzheimer's Association
  12. Alzheimer's Drug Discovery Foundation
  13. Araclon Biotech
  14. BioClinica, Inc.
  15. Biogen
  16. Bristol-Myers Squibb Company
  17. CereSpir, Inc.
  18. Cogstate
  19. Eisai Inc.
  20. Elan Pharmaceuticals, Inc.
  21. Eli Lilly and Company
  22. EuroImmun
  23. F. Hoffmann-La Roche Ltd
  24. Genentech, Inc.
  25. Fujirebio
  26. GE Healthcare
  27. IXICO Ltd.
  28. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  29. Johnson & Johnson Pharmaceutical Research & Development LLC.
  30. Lumosity
  31. Lundbeck
  32. Merck Co., Inc.
  33. Meso Scale Diagnostics, LLC.
  34. NeuroRx Research
  35. Neurotrack Technologies
  36. Novartis Pharmaceuticals Corporation
  37. Pfizer Inc.
  38. Piramal Imaging
  39. Servier
  40. Takeda Pharmaceutical Company
  41. Transition Therapeutics
  42. State Key Laboratory of Neurobiology of Ministry of Education, Fudan University

Ask authors/readers for more resources

As a marker of neuroaxonal injury, neurofilament light (NFL) in blood is robustly elevated in many neurodegenerative conditions. We aimed to discover single nucleotide polymorphisms (SNPs) associated with longitudinal changes in plasma NFL levels that affect the risk of developing neurodegenerative disease and clinical disease progression. 545 eligible non-Hispanic white participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with longitudinal plasma NFL data were included. Three SNPs (rs16840041, p=4.50x10(-8); rs2269714, p=4.50x10(-8); rs2269715, p=4.83x10(-8)) in CD1A were in high linkage disequilibrium (LD) and significantly associated with the increase in plasma NFL levels. We demonstrate a promoting effect of rs16840041-A on clinical disease progression (p = 0.006). Moreover, the minor allele (A) of rs16840041 was significantly associated with accelerated decline in [F-18] Fluorodeoxyglucose (FDG) (estimate -1.6% per year [95% CI -0.6 to -2.6], p=0.0024). CD1A is a gene involved in longitudinal changes in plasma NFL levels and AD-related phenotypes among non-demented elders. Given the potential effects of these variants, CD1A should be further investigated as a gene of interest in neurodegenerative diseases and as a potential target for monitoring disease trajectories and treating disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available